Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
You can stay off the roller coaster by looking for companies that have a stable track record, with growth prospects that are reasonable rather than dramatic. Despite the drama that is built into the biotech business, there are companies that proceed calmly and offer investors reliable returns.
We have selected five top biotech stocks that are poised for growth for 2017. All figures are current as of August 11, 2017.
1. Celgene Corp.
) focuses on cancer and inflammatory diseases. The company not only develops its own products; it collaborates with other large drug makers to bring products to market.
Revenues were higher in the last quarter, and operating income increased steadily. This has been a stable company, especially considering biotech carries high risk.
The stock started 2017 with steady gains through April, but gave back its gains. At the beginning of June, the stock found support and began rising again. It has been rising since.
The stock could perform well in the second half of 2017. The company has financial expectations for the remainder of the year that are above analyst estimates.
Avg. Volume: 3,923,142
Market Cap: $103.92 billion
PE Ratio (TTM): 49.88
EPS (TTM): 2.66
1y Target Est: 150.17
Read more: Top 5 Biotech Stocks as of August 2017 | Investopedia http://www.investopedia.com/investing/biotech-stocks/#ixzz4rp7GC6Pw
Follow us: Investopedia on Facebook
提示: 本博文来自于 Stock 版